ACCELERATING RETURNS. NAVIGATING COMPLEX LANDSCAPES.
Financial metrics only tell half the story. FDA regulatory risk is one of the most consequential variables in shaping asset value.

We specialize in identifying expedited strategies to maximize asset valuation and shorten timelines.

We intervene when assets stall. We deploy senior expertise to resolve clinical holds and negotiate directly with FDA review divisions to get the product moving again.

Our team is comprised of former FDA senior officials, industry veterans, and academic stakeholders with 250+ years of combined insight.

We created internal training materials for FDA Medical Officers and Pre-Market Reviewers that are still used to this day.

We helped over a dozen companies secure marketing authorizations, including the first-ever FDA Breakthrough Device Designation (BDD) for treating Alzheimer’s disease.

Success belongs to those astute enough to keep pace with rapid advancements in FDA regulatory policy. We help your portfolio companies leverage new and novel policies to their advantage, utilizing these shifts to expedite approvals and reduce clinical burdens and associated costs.

We uncover what the pitch deck hides. Our deep-dive audits of clinical datasets and correspondence substantiate scientific claims to de-risk your entry.

Your portfolio’s next FDA hurdle shouldn’t be a surprise. Let’s meet to discuss the specific regulatory or clinical bottlenecks currently threatening your assets and define a roadmap to clear them.
Copyright © 2026 FDA Partners - All Rights Reserved.
FDA Partners - contact@fda-partners.com